Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
ERNEXA THERAPEUTICS INC (ERNA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.83-8.04%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for ERNA yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Complete public offering of 19 million shares | The company plans to raise money by selling 19 million shares. | Intact | Public offering fails to complete by 2026-Q2 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextNewly stated in 2026-Q1. The company entered a placement agency agreement to raise capital via a public offering of 19 million shares. Financials show continued net losses and negative cash from operations, indicating ongoing capital needs. The priority is newly stated and capital raising is in progress. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making business rather than an established durable compounder. The multi-year view is in a watch state, with low confidence and recent results well below its industry cohort.
The valuation model shows a durable premium versus peers, but confidence in that measure is low. The evidence does not explain what expectations support the premium, so how much optimism is already priced in is unclear.
Near term, continued operating losses and negative cash from operations point to ongoing funding needs, despite a recent improvement in operating loss. The company is raising capital and addressing a Nasdaq minimum-bid-price notice, while the risk of another earnings miss is elevated. The stronger Healthcare sector backdrop is a support, but it does not resolve ERNA’s company-specific issues.
Over the next few quarters, the thesis hinges on whether ERNA can reduce losses and cash burn while addressing listing compliance and its capital needs. A weakening jobs report could weigh on cyclical shares, while strong results from sector bellwethers could sustain Healthcare momentum; misses or weaker guidance from those companies could remove that support.
For the 1-to-3-year view, ERNA remains a fragile, high-risk case: loss control, financing, and listing compliance are central, and the evidence is limited. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Resolve Nasdaq minimum bid price issue | It aims to fix Nasdaq listing problems. | Intact | Bid price falls below $1.00 per share next quarter | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextNewly stated in 2026-Q1. The company received a Nasdaq notice for failing to maintain the minimum bid price of $1.00 per share. No revenue data is available, but net losses and operating losses have continued. The priority is newly stated and the regulatory risk remains unresolved. Delivery assessment Oct 31, 2026 |
Reduce operating losses and cash burn | A primary condition in ERNEXA THERAPEUTICS INC's published investment case. The stated target is Operating loss and cash burn improve from -$5.59M and -$2.26M in 2026-Q1. | Broken | Losses and cash burn worsen or stay at 2026-Q1 levels | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 7 of last 7 quarters. Operating income worsened from negative $2.7M in 2024-Q4 to negative $5.59M in 2026-Q1, then improved to negative $4.1M in 2026-Q2. Cash from operations remained negative, ranging from $3.55M to $4.15M negative. The company continues to experience operating losses and cash burn, indicating limited progress in controlling costs. Delivery assessment Oct 31, 2026 |
Advance ERNA-101 toward IND filing | Ernexa is advancing its cancer drug ERNA-101 toward a Q3 filing. | Intact | IND filing delayed beyond Q3 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.86 → $-1.86 · observed estimates
Unavailable → Unavailable · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.86 | Unavailable | 1 / 0 |
| 2026-07-25 | $-1.86 | Unavailable | 1 / 0 |
| 2026-07-26 | $-1.86 | Unavailable | 1 / 0 |
| 2026-07-27 | $-1.86 | Unavailable | 1 / 0 |
| 2026-07-28 | $-1.86 | Unavailable | 1 / 0 |
| 2026-07-29 | $-1.86 | $0 | 1 / 1 |
| 2026-07-30 | $-1.86 | $0 | 1 / 1 |
| 2026-07-31 | $-1.86 | Unavailable | 1 / 0 |
| 2026-08-01 | $-1.86 | Unavailable | 1 / 0 |
| 2026-08-02 | $-1.86 | $0 | 1 / 1 |
| 2026-08-03 | $-1.86 | $0 | 1 / 1 |
| 2026-08-04 | $-1.86 | $0 | 1 / 1 |
| 2026-08-05 | $-1.86 | $0 | 1 / 1 |
| 2026-08-06 | $-1.86 | $0 | 1 / 1 |
| 2026-08-07 | $-1.86 | Unavailable | 1 / 0 |
| 2026-08-08 | $-1.86 | $0 | 1 / 1 |
| 2026-08-09 | $-1.86 | $0 | 1 / 1 |
| 2026-08-10 | $-1.86 | $0 | 1 / 1 |
| 2026-08-11 | $-1.86 | $0 | 1 / 1 |
| 2026-08-12 | $-1.86 | $0 | 1 / 1 |
| 2026-08-13 | $-1.86 | $0 | 1 / 1 |
| 2026-08-14 | $-1.86 | Unavailable | 1 / 0 |
| 2026-08-15 | $-1.86 | Unavailable | 1 / 0 |
| 2026-08-16 | $-1.86 | Unavailable | 1 / 0 |
| 2026-08-17 | $-1.86 | Unavailable | 1 / 0 |
| 2026-08-18 | $-1.86 | Unavailable | 1 / 0 |
| 2026-08-19 | $-1.86 | Unavailable | 1 / 0 |
| 2026-08-20 | $-1.86 | Unavailable | 1 / 0 |
| 2026-08-21 | $-1.86 | Unavailable | 1 / 0 |
| 2026-08-22 | $-1.86 | Unavailable | 1 / 0 |
| 2026-08-23 | $-1.86 | Unavailable | 1 / 0 |
| 2026-08-24 | $-1.86 | Unavailable | 1 / 0 |
| 2026-08-25 | $-1.86 | Unavailable | 1 / 0 |
| 2026-08-26 | $-1.86 | Unavailable | 1 / 0 |
| 2026-08-27 | $-1.86 | Unavailable | 1 / 0 |
| 2026-08-28 | $-1.86 | Unavailable | 1 / 0 |
| 2026-08-29 | $-1.86 | Unavailable | 1 / 0 |
| 2026-08-30 | $-1.86 | Unavailable | 1 / 0 |
| 2026-08-31 | $-1.86 | Unavailable | 1 / 0 |
| 2026-09-01 | $-1.86 | Unavailable | 1 / 0 |
| 2026-09-02 | $-1.86 | Unavailable | 1 / 0 |
| 2026-09-03 | $-1.86 | Unavailable | 1 / 0 |
| 2026-09-04 | $-1.86 | Unavailable | 1 / 0 |
| 2026-09-05 | $-1.86 | Unavailable | 1 / 0 |
| 2026-09-06 | $-1.86 | Unavailable | 1 / 0 |
| 2026-09-07 | $-1.86 | Unavailable | 1 / 0 |
| 2026-09-08 | $-1.86 | Unavailable | 1 / 0 |
| 2026-09-09 | $-1.86 | Unavailable | 1 / 0 |
| 2026-09-10 | $-1.86 | Unavailable | 1 / 0 |
| 2026-09-11 | $-1.86 | Unavailable | 1 / 0 |
| 2026-09-12 | $-1.86 | Unavailable | 1 / 0 |
| 2026-09-13 | $-1.86 | Unavailable | 1 / 0 |
| 2026-09-14 | $-1.86 | Unavailable | 1 / 0 |
| 2026-09-15 | $-1.86 | Unavailable | 1 / 0 |
| 2026-09-16 | $-1.86 | Unavailable | 1 / 0 |
| 2026-09-17 | $-1.86 | Unavailable | 1 / 0 |
| 2026-09-18 | $-1.86 | Unavailable | 1 / 0 |
| 2026-09-19 | $-1.86 | Unavailable | 1 / 0 |
| 2026-09-20 | $-1.86 | Unavailable | 1 / 0 |
| 2026-09-21 | $-1.86 | Unavailable | 1 / 0 |
| 2026-09-22 | $-1.86 | Unavailable | 1 / 0 |
| 2026-09-23 | $-1.86 | Unavailable | 1 / 0 |
| 2026-09-24 | $-1.86 | Unavailable | 1 / 0 |
| 2026-09-25 | $-1.86 | Unavailable | 1 / 0 |
| 2026-09-26 | $-1.86 | Unavailable | 1 / 0 |
| 2026-09-27 | $-1.86 | Unavailable | 1 / 0 |
| 2026-09-28 | $-1.86 | Unavailable | 1 / 0 |
| 2026-09-29 | $-1.86 | Unavailable | 1 / 0 |
| 2026-09-30 | $-1.86 | Unavailable | 1 / 0 |
| 2026-10-01 | $-1.86 | Unavailable | 1 / 0 |
| 2026-10-02 | $-1.86 | Unavailable | 1 / 0 |
| 2026-10-03 | $-1.86 | Unavailable | 1 / 0 |
| 2026-10-04 | $-1.86 | Unavailable | 1 / 0 |
| 2026-10-05 | $-1.86 | Unavailable | 1 / 0 |
| 2026-10-06 | $-1.86 | Unavailable | 1 / 0 |
| 2026-10-07 | $-1.86 | Unavailable | 1 / 0 |
| 2026-10-08 | $-1.86 | Unavailable | 1 / 0 |
| 2026-10-09 | $-1.86 | Unavailable | 1 / 0 |
| 2026-10-10 | $-1.86 | Unavailable | 1 / 0 |
| 2026-10-11 | $-1.86 | Unavailable | 1 / 0 |
| 2026-10-12 | $-1.86 | Unavailable | 1 / 0 |
| 2026-10-13 | $-1.86 | Unavailable | 1 / 0 |
| 2026-10-14 | $-1.86 | Unavailable | 1 / 0 |
| 2026-10-15 | $-1.86 | Unavailable | 1 / 0 |
| 2026-10-16 | $-1.86 | Unavailable | 1 / 0 |
| 2026-10-17 | $-1.86 | Unavailable | 1 / 0 |
| 2026-10-18 | $-1.86 | Unavailable | 1 / 0 |
| 2026-10-19 | $-1.86 | Unavailable | 1 / 0 |
| 2026-10-20 | $-1.86 | Unavailable | 1 / 0 |
| 2026-10-21 | $-1.86 | Unavailable | 1 / 0 |
| 2026-10-22 | $-1.86 | Unavailable | 1 / 0 |
| 2026-10-23 | $-1.86 | Unavailable | 1 / 0 |
| 2026-10-24 | $-1.86 | Unavailable | 1 / 0 |
| 2026-10-25 | $-1.86 | Unavailable | 1 / 0 |
| 2026-10-26 | $-1.86 | Unavailable | 1 / 0 |
| 2026-10-27 | $-1.86 | Unavailable | 1 / 0 |
| 2026-10-28 | $-1.86 | Unavailable | 1 / 0 |
| 2026-10-29 | $-1.86 | Unavailable | 1 / 0 |
| 2026-10-30 | $-1.86 | Unavailable | 1 / 0 |
| 2026-10-31 | $-1.86 | Unavailable | 1 / 0 |
| 2026-11-01 | $-1.86 | Unavailable | 1 / 0 |
| 2026-11-02 | $-1.86 | Unavailable | 1 / 0 |
| 2026-11-03 | $-1.86 | Unavailable | 1 / 0 |
| 2026-11-04 | $-1.86 | Unavailable | 1 / 0 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Nov 6, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.